Title(s):
EAZ171. Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
Alliance A221702. ARM: Axillary Reverse Mapping- A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping
Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CCTG MA.39. A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Investigator(s): Mitchel Fromm, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s): 
NSABP B-51/RTOG 1304. A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
|Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU A011202. A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU EA1131. A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
NRG-BR003. A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
NRG-BR002. A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Investigator(s): Mitchell Fromm, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CTSU A011502. A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
17013. Mammaprint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
A221505. Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Investigator(s): Mitchel Fromm, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
A211601. Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
SWOG 1501. Prospective evaluation of carvedilol in prevention of cardiac toxicity in patients with metastatic HER2 + breast cancer, phase III
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348